LOM Asset Management Ltd Buys 15,425 Shares of Novo Nordisk A/S $NVO

LOM Asset Management Ltd grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1,448.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,490 shares of the company’s stock after purchasing an additional 15,425 shares during the period. LOM Asset Management Ltd’s holdings in Novo Nordisk A/S were worth $915,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. True Wealth Design LLC increased its stake in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares during the last quarter. Guerra Advisors Inc purchased a new position in shares of Novo Nordisk A/S in the third quarter valued at $25,000. Strengthening Families & Communities LLC bought a new stake in Novo Nordisk A/S in the third quarter worth $30,000. NewSquare Capital LLC raised its stake in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares in the last quarter. Finally, Allianz SE raised its stake in Novo Nordisk A/S by 70.0% during the third quarter. Allianz SE now owns 578 shares of the company’s stock valued at $32,000 after purchasing an additional 238 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on NVO shares. HSBC restated a “hold” rating and set a $54.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. TD Cowen restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Five investment analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $53.93.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $39.02 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The stock’s fifty day moving average is $51.68 and its two-hundred day moving average is $52.48. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $89.03. The company has a market capitalization of $174.22 billion, a PE ratio of 11.24 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is currently 52.74%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley raised NVO to Equal Weight, reducing downside concerns from that shop and providing some support for the shares. Novo Nordisk A/S (NYSE:NVO) Raised to Equal Weight at Morgan Stanley
• Positive Sentiment: Market reaction to the FDA’s tighter scrutiny of telehealth GLP‑1 advertisers lifted NVO as investors expect larger incumbent manufacturers to benefit if smaller/telehealth competitors face limits. Novo Nordisk (NVO) Stock Jumps 3% as FDA Cracks Down on Telehealth GLP-1 Advertisers
• Neutral Sentiment: Goldman Sachs reiterated a Neutral rating on NVO, leaving the firm’s guidance unchanged and offering little directional push. The Goldman Sachs Group Reaffirms “Neutral” Rating for Novo Nordisk A/S (NYSE:NVO)
• Neutral Sentiment: Market commentary is debating Novo Nordisk’s valuation after the recent share decline; some pieces argue pessimism may be overdone while others call for catalyst clarity — this keeps near-term sentiment mixed. Novo Nordisk (NYSE:NVO) Valuation Debate Lingers As Market Awaits Catalyst Clarity
• Neutral Sentiment: Analysis pieces are questioning whether the recent selloff has priced in too much pessimism, which can attract value‑oriented buyers if fundamentals hold. Is Novo Nordisk (NYSE:NVO) Now Pricing In Too Much Pessimism After Share Price Slump
• Negative Sentiment: FDA has issued another warning letter to Novo Nordisk over an “Only One Ozempic” ad and broader GLP‑1 advertising concerns — increased regulatory scrutiny of marketing claims raises compliance risk and potential reputational damage. Novo Nordisk slammed with another FDA letter for ‘Only One Ozempic’ ad
• Negative Sentiment: Additional reporting confirms the FDA’s second warning over GLP‑1 ads, reinforcing regulatory/headline risk that could pressure sentiment and invite closer agency oversight. FDA sends Novo Nordisk 2nd warning over GLP-1 ads
• Negative Sentiment: The American Hospital Association urged HRSA to block Novo Nordisk’s new claims-data submission policy for 340B hospitals, signaling potential pushback from hospital customers and possible distribution/contracting friction. AHA urges HRSA to stop Novo Nordisk’s new claims-data submission policy on 340B hospitals from going into effect
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Novo Nordisk, which could foreshadow litigation or shareholder claims and add legal uncertainty. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.